Sign in to fuzzto save your conversations, follow your research and come back anytime.
Epigral
EPIGRAL
NSE
BSE
NSEBSESectorChemicals
1,225.20
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Epigral Ltd shows a strong operational rebound in Q1 FY27, with revenue and margins recovering from a mid-year slump, though capital efficiency and equity returns remain under pressure.
EBITDA recovers from ₹103 Cr to ₹179 Cr from Q3 FY26 to Q1 FY27, showing strong operational rebound.
ROE falls from 25% to 12% from Q1 FY26 to Q1 FY27, highlighting equity return erosion.
Plant utilization climbs from 73% to 80% from Q1 FY26 to Q1 FY27, reflecting steady demand absorption.
PAT margin contracts from 26% to 14% from Q1 FY26 to Q1 FY27, showing profitability remains below peak levels.
Finance costs drop from ₹23 Cr to ₹7 Cr from Q1 FY26 to Q1 FY27, highlighting effective debt management.
EPS drops from ₹37.2 to ₹23.0 from Q1 FY26 to Q1 FY27, indicating earnings have not fully recovered.
Gross margin improves from 33% to 39% from Q3 FY26 to Q1 FY27, indicating better input cost control.
ROCE declines from 24% to 16% from Q1 FY26 to Q1 FY27, signaling pressure on capital efficiency.
Revenue grows from ₹603 Cr to ₹709 Cr from Q3 FY26 to Q1 FY27, confirming top-line stabilization.
Net profit falls from ₹160 Cr to ₹99 Cr from Q1 FY26 to Q1 FY27, reflecting incomplete profit normalization.
